Financials data is unavailable for this security.
View more
Year on year Dermapharm Holding SE had net income fall -53.54% from 134.24m to 62.37m despite a 10.79% increase in revenues from 1.02bn to 1.14bn. An increase in the selling, general and administrative costs as a percentage of sales from 28.39% to 36.87% was a component in the falling net income despite rising revenues.
| Gross margin | 64.66% |
|---|---|
| Net profit margin | 7.71% |
| Operating margin | 17.78% |
| Return on assets | 4.17% |
|---|---|
| Return on equity | 16.04% |
| Return on investment | 5.01% |
More ▼
Cash flow in EURView more
In 2023, Dermapharm Holding SE increased its cash reserves by 5.10%, or 7.71m. The company earned 218.60m from its operations for a Cash Flow Margin of 19.25%. In addition the company generated 204.54m cash from financing while 415.43m was spent on investing.
| Cash flow per share | 3.49 |
|---|---|
| Price/Cash flow per share | 10.56 |
| Book value per share | 10.84 |
|---|---|
| Tangible book value per share | -9.56 |
More ▼
Balance sheet in EURView more
| Current ratio | 1.66 |
|---|---|
| Quick ratio | 0.7368 |
| Total debt/total equity | 1.76 |
|---|---|
| Total debt/total capital | 0.6352 |
More ▼
Growth rates in EUR
Year on year, growth in earnings per share excluding extraordinary items dropped -53.54%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 52.30% |
| EPS growth(5 years) | -3.86 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -4.72 |
More ▼
